J&J Drug Lowers Prostate Cancer Spread and Mortality Rates in Late-Stage Study

• 8.9% of patients on the Erleada combination had little to no cancer at surgery versus only 1% on hormone therapy alone, with the treatment reducing recurrence or death risk by 20%
• Extended treatment (one full year) nearly doubled the time before patients needed additional therapy to over six years and reduced recurrence/death risk by 29%
• The drug would be the first androgen receptor pathway inhibitor approved for localized high-risk prostate cancer, addressing a major unmet need as nearly half of patients currently see cancer return after standard surgery and radiation

Summary

Johnson & Johnson presented late-stage trial data showing its prostate cancer drug Erleada (apalutamide) significantly improved outcomes when combined with hormone-blocking therapy before and after prostate surgery.

Key Findings:

The five-year study of over 2,000 patients with high-risk localized or locally advanced prostate cancer demonstrated:

• 8.9% of patients receiving the combination therapy had little to no detectable cancer at surgery versus 1% on hormone therapy alone—a nine-fold improvement
• The combination reduced disease recurrence or death risk by 20%
• Extended one-year treatment regimen reduced recurrence and death risk by 29%
• Patients on extended combination therapy went more than six years before requiring subsequent treatment—nearly double the time compared to hormone therapy alone

Market Context:

Approximately 40% of the 330,000 annual U.S. prostate cancer diagnoses are high-risk cases. Currently, nearly 50% of patients undergoing standard prostate-removal surgery and radiation experience cancer recurrence.

Researchers called the data "paradigm changing," as no androgen receptor pathway inhibitors (ARPIs) are currently approved for localized high-risk prostate cancer. The safety profile remained consistent with previous studies, with common side effects including hot flushes, urinary incontinence, and erectile dysfunction.

Erleada, approved in 2018, competes with Pfizer's Xtandi and Bayer's Nubeqa in the ARPI class. J&J plans to seek expanded global regulatory approvals for earlier-stage prostate cancer treatment, potentially opening a significant new market segment for the drug.